Mohammad Alashqar Shares Fitusiran Review for Hemophilia A and B, With or Without Inhibitors
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
”Grateful to share that my review paper, “Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors,” has been published online today (12/26)
Sincere thanks to everyone who supported me throughout this journey—especially Dr. Milap Nahata for his mentorship, guidance, and invaluable feedback.
This work would not have been possible without such support.
Looking forward to continuing contributions to hemophilia and thrombosis research.”
Read the full article here.
Article: Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors
Authors: Mohammad Alashqar, Milap Nahata
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 13, 2026, 17:41Peter Zdziarski: Glanzmann’s Research Foundation Listed as GT Patient Organization on NORD
-
Apr 13, 2026, 17:39Nathan Connell: Why Prophylaxis in vWD Has Historically Lagged Behind Established Practice in Hemophilia
-
Apr 13, 2026, 17:38Tareq Abadl: A Blood Transfusion Can Cause a Delayed Platelet Crash
-
Apr 13, 2026, 13:33Tetsumei Urano: Join for the ISTH Educational Programs at APSTH 2026 in Japan
-
Apr 13, 2026, 13:26Salih Ehsan: Neutrophil Behavior Across Pregnancy and Infection Assessment
-
Apr 13, 2026, 13:20Denis Oduor: Autologous Blood Transfusion – A Significant Moment in Patient Care and Choice
-
Apr 13, 2026, 13:13Tareq Abadl: How the Immune System Turns Against the Body in Autoimmune Diseases
-
Apr 13, 2026, 13:13Yousra Tera: Celebrating a Lasting Impact on Future Generations
-
Apr 13, 2026, 13:07Laura Dormer: Real-World Insights into Treatment and Costs in VWD from FORvWARD Study